Sartorius Stedim Biotech provides preliminary first-half financial key figures and raises forecast for 2021

Rhea-AI Summary

Sartorius Stedim Biotech reported a projected 61% revenue growth for the first half of 2021, alongside an underlying EBITDA margin between 36.0% and 36.5%. This performance reflects robust order intake and stable supply chains. The company has revised its full-year forecast upwards, estimating 48% sales growth (previously 38%) and maintaining an EBITDA margin of about 36%. Risks associated with the pandemic persist, affecting guidance reliability. Detailed half-year figures will be released on July 21, 2021.

Positive

• Projected revenue growth of 61% in constant currencies for H1 2021.
• Raised full-year sales growth forecast to 48% from 38%.

Negative

• Increased uncertainty due to pandemic impacts on supply chains.
• Future development statements are speculative and carry risks.

AUBAGNE, France, July 5, 2021 /PRNewswire/ -- For the first six months ended June 30, the company expects revenue growth to be approximately 61% in constant currencies with an underlying EBITDA margin¹ in the range of 36.0 to 36.5%. This better-than-expected performance is broad-based across all geographies and is backed by continuously strong order intake, stable supply chains, and expanded production capacities.

Based on the dynamic business development so far and on increasingly robust prospects for the second half, Sartorius Stedim Biotech is raising its forecast for the full year: The company now projects consolidated sales growth of around 48% (previously 38%) and an underlying EBITDA margin¹ of about 36% (previously about 34%). All figures are given in constant currencies as in the past.

Due to the pandemic, this guidance continues to be subject to higher uncertainty than usual and is particularly based on the assumptions that supply chains will remain stable and production lines will stay up and running. The mid-term targets up to 2025 that were updated in January 2021 are unaffected by these adjustments.

Sartorius Stedim Biotech will publish the full set of half-year figures for 2021 as scheduled on July 21, 2021, and will hold a conference call on the same day.

1 Sartorius Stedim Biotech publishes alternative performance measures that are not defined by international accounting standards. These are determined with the aim of improving the comparability of business performance over time and within the industry.

• Underlying EBITDA: earnings before interest, taxes, depreciation and amortization and adjusted for extraordinary items

This notification according to Article 17 MAR contains statements about the future development of the Sartorius Stedim Biotech Group. The content of these statements cannot be guaranteed as they are based on assumptions and estimates that harbor certain risks and uncertainties. This is a translation of the original French-language announcement. Sartorius Stedim Biotech shall not assume any liability for the correctness of this translation. The original French announcement is the legally binding version. Furthermore, Sartorius Stedim Biotech reserves the right not to be responsible for the topicality, correctness, completeness or quality of the information provided. Liability claims regarding damage caused by the use of any information provided, including any kind of information which is incomplete or incorrect, will therefore be rejected.

Contact
Petra Kirchhoff
Head of Corporate Communications and Investor Relations
+49 (0)551.308.1686
petra.kirchhoff@sartorius.com
sartorius.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/sartorius-stedim-biotech-provides-preliminary-first-half-financial-key-figures-and-raises-forecast-for-2021-301325602.html

SOURCE Sartorius Stedim Biotech S.A.

FAQ

What is Sartorius Stedim Biotech's revenue growth forecast for 2021?

Sartorius Stedim Biotech forecasts a revenue growth of approximately 48% for 2021.

When will Sartorius Stedim Biotech release its half-year financial figures?

Sartorius Stedim Biotech will publish its half-year financial figures on July 21, 2021.

What is the underlying EBITDA margin forecast for Sartorius Stedim Biotech in 2021?

The underlying EBITDA margin forecast for Sartorius Stedim Biotech in 2021 is about 36%.

What major factors influenced Sartorius Stedim Biotech's financial performance?

Strong order intake, stable supply chains, and expanded production capacities influenced the financial performance.

What are the risks associated with Sartorius Stedim Biotech's guidance?

The guidance is subject to higher uncertainty due to the pandemic impacting supply chains and production stability.